Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Duhlmeier, R; Deegen, E; Fuhrmann, H; Widdel, A; Sallmann, HP
   Glucose-dependent insulinotropic polypeptide (GIP) and the enteroinsular axis in equines (Equus caballus)
   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR AND INTEGRATIVE PHYSIOLOGY
   
   R. Duhlmeier et al., "Glucose-dependent insulinotropic polypeptide (GIP) and the enteroinsular axis in equines (Equus caballus)", COMP BIOC A, 129(2-3), 2001, pp. 563-575
2. Meneilly, GS; McIntosh, CHS; Pederson, RA; Habener, JF; Gingerich, R; Egan, JM; Elahi, D
   Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake inelderly patients with diabetes
   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
   
   G.S. Meneilly et al., "Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake inelderly patients with diabetes", J GERONT A, 56(11), 2001, pp. M681-M685
3. Vara, E; Arias-Diaz, J; Garcia, C; Balibrea, JL; Blazquez, E
   Glucagon-like peptide-1(7-34) amide stimulates surfactant secretion in human type II pneumocytes
   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
   
   E. Vara et al., "Glucagon-like peptide-1(7-34) amide stimulates surfactant secretion in human type II pneumocytes", AM J R CRIT, 163(4), 2001, pp. 840-846
4. Creutzfeldt, W
   The entero-insular axis in type 2 diabetes - incretins as therapeutic agents
   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
   
   W. Creutzfeldt, "The entero-insular axis in type 2 diabetes - incretins as therapeutic agents", EXP CL E D, 109, 2001, pp. S288-S303
5. Wettergren, A
   Glucagon-like peptide-1 - Gastrointestinal function and possible mechanismof action
   DANISH MEDICAL BULLETIN
   
   A. Wettergren, "Glucagon-like peptide-1 - Gastrointestinal function and possible mechanismof action", DAN MED B, 48(1), 2001, pp. 19-28
6. Guenifi, A; Ahren, B; Abdel-Halim, SM
   Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro
   PANCREAS
   
   A. Guenifi et al., "Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro", PANCREAS, 22(1), 2001, pp. 58-64
7. Knudsen, LB; Agerso, H; Bjenning, C; Bregenholt, S; Carr, RD; Godtfredsen, C; Holst, JJ; Huusfeldt, PO; Larsen, MO; Larsen, PJ; Nielsen, PF; Ribel, U; Rolin, B; Romer, J; Sturis, J; Wilken, M; Kristensen, P
   GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes:selection of NN2211 for clinical development
   DRUGS OF THE FUTURE
   
   L.B. Knudsen et al., "GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes:selection of NN2211 for clinical development", DRUG FUTURE, 26(7), 2001, pp. 677-685
8. Parkes, D; Jodka, C; Smith, P; Nayak, S; Rinehart, L; Gingerich, R; Chen, K; Young, A
   Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1
   DRUG DEVELOPMENT RESEARCH
   
   D. Parkes et al., "Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1", DRUG DEV R, 53(4), 2001, pp. 260-267
9. O'Harte, FPM; Mooney, MH; Kelly, CMN; McKillop, AM; Flatt, PR
   Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice
   REGULATORY PEPTIDES
   
   F.P.M. O'Harte et al., "Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice", REGUL PEPT, 96(3), 2001, pp. 95-104
10. Moro, F; Levenez, F; Durual, S; Plaisancie, P; Thim, L; Giraud, AS; Cuber, JC
    Secretion of the trefoil factor TFF3 from the isolated vascularly perfusedrat colon
    REGULATORY PEPTIDES
    
    F. Moro et al., "Secretion of the trefoil factor TFF3 from the isolated vascularly perfusedrat colon", REGUL PEPT, 101(1-3), 2001, pp. 35-41
11. Larsen, J; Hylleberg, B; Ng, K; Damsbo, P
    Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtainacceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
    DIABETES CARE
    
    J. Larsen et al., "Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtainacceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment", DIABET CARE, 24(8), 2001, pp. 1416-1421
12. Holst, JJ; Orskov, C
    Incretin hormones - an update
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
    
    J.J. Holst e C. Orskov, "Incretin hormones - an update", SC J CL INV, 61, 2001, pp. 75-85
13. Choi, YH; Anderson, GH
    An interaction between hypothalamic glucagon-like peptide-1 and macronutrient composition determines food intake in rats
    JOURNAL OF NUTRITION
    
    Y.H. Choi e G.H. Anderson, "An interaction between hypothalamic glucagon-like peptide-1 and macronutrient composition determines food intake in rats", J NUTR, 131(6), 2001, pp. 1819-1825
14. Toft-Nielsen, MB; Damholt, MB; Madsbad, S; Hilsted, LM; Hughes, TE; Michelsen, BK; Holst, JJ
    Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
    JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    
    M.B. Toft-Nielsen et al., "Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients", J CLIN END, 86(8), 2001, pp. 3717-3723
15. Toft-Nielsen, MB; Madsbad, S; Holst, JJ
    Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    
    M.B. Toft-Nielsen et al., "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes", J CLIN END, 86(8), 2001, pp. 3853-3860
16. Bertin, E; Arner, P; Bolinder, J; Hagstrom-Toft, E
    Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo
    JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    
    E. Bertin et al., "Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo", J CLIN END, 86(3), 2001, pp. 1229-1234
17. Lovshin, J; Estall, J; Yusta, B; Brown, TJ; Drucker, DJ
    Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    J. Lovshin et al., "Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling", J BIOL CHEM, 276(24), 2001, pp. 21489-21499
18. Villanueva-Penacarrillo, ML; Marquez, L; Gonzalez, N; Diaz-Miguel, M; Valverde, I
    Effect of GLP-1 on lipid metabolism in human adipocytes
    HORMONE AND METABOLIC RESEARCH
    
    M.L. Villanueva-Penacarrillo et al., "Effect of GLP-1 on lipid metabolism in human adipocytes", HORMONE MET, 33(2), 2001, pp. 73-77
19. Ranganath, LR; Beety, JM; Wright, J; Morgan, LM
    Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects
    HORMONE AND METABOLIC RESEARCH
    
    L.R. Ranganath et al., "Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects", HORMONE MET, 33(1), 2001, pp. 57-61
20. Garcia-Flores, M; Zueco, JA; Alvarez, E; Blazquez, E
    Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development
    EUROPEAN JOURNAL OF BIOCHEMISTRY
    
    M. Garcia-Flores et al., "Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development", EUR J BIOCH, 268(3), 2001, pp. 514-520
21. Rocca, AS; LaGreca, J; Kalitsky, J; Brubaker, PL
    Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1
    ENDOCRINOLOGY
    
    A.S. Rocca et al., "Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1", ENDOCRINOL, 142(3), 2001, pp. 1148-1155
22. Drucker, DJ
    Minireview: The glucagon-like peptides
    ENDOCRINOLOGY
    
    D.J. Drucker, "Minireview: The glucagon-like peptides", ENDOCRINOL, 142(2), 2001, pp. 521-527
23. Lynn, FC; Pamir, N; Ng, EHC; McIntosh, CHS; Kieffer, TJ; Pederson, RA
    Defective glucose-dependent insulinotropic polypeptide receptor expressionin diabetic fatty Zucker rats
    DIABETES
    
    F.C. Lynn et al., "Defective glucose-dependent insulinotropic polypeptide receptor expressionin diabetic fatty Zucker rats", DIABETES, 50(5), 2001, pp. 1004-1011
24. Ritzel, R; Schulte, M; Porksen, N; Nauck, MS; Holst, JJ; Juhl, C; Marz, W; Schmitz, O; Schmiegel, WH; Nauck, MA
    Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance
    DIABETES
    
    R. Ritzel et al., "Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance", DIABETES, 50(4), 2001, pp. 776-784
25. Meier, JJ; Huking, K; Holst, JJ; Deacon, CF; Schmiegel, WH; Nauck, MA
    Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
    DIABETES
    
    J.J. Meier et al., "Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes", DIABETES, 50(11), 2001, pp. 2497-2504
26. Larsen, PJ; Fledelius, C; Knudsen, LB; Tang-Christensen, M
    Systemic administration of the long-acting GLP-1 derivative NN2211 induceslasting and reversible weight loss in both normal and obese rats
    DIABETES
    
    P.J. Larsen et al., "Systemic administration of the long-acting GLP-1 derivative NN2211 induceslasting and reversible weight loss in both normal and obese rats", DIABETES, 50(11), 2001, pp. 2530-2539
27. Nagakura, T; Yasuda, N; Yamazaki, K; Ikuta, H; Yoshikawa, S; Asano, O; Tanaka, I
    Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient fischer rats
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    T. Nagakura et al., "Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient fischer rats", BIOC BIOP R, 284(2), 2001, pp. 501-506
28. 
    Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidylpeptidase IV in the treatment of non-insulin-dependent diabetes mellitus
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    EXPERT OP T, 10(12), 2000, pp. 1937-1942
29. D'Alessio, D
    Glucagon-like peptide 1 (GLP-1) in diabetes and aging
    JOURNAL OF ANTI-AGING MEDICINE
    
    D. D'Alessio, "Glucagon-like peptide 1 (GLP-1) in diabetes and aging", J ANTI-AG M, 3(3), 2000, pp. 329-333
30. Nauck, M; Hahn, S; Sauerwald, A; Schmiegel, W
    Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    M. Nauck et al., "Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients", EXP CL E D, 108(2), 2000, pp. 72-75
31. Hedetoft, C; Sheikh, SP; Larsen, S; Holst, JJ
    Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis
    PANCREAS
    
    C. Hedetoft et al., "Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis", PANCREAS, 20(1), 2000, pp. 25-31
32. Perfetti, R; Merkel, P
    Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function
    EUROPEAN JOURNAL OF ENDOCRINOLOGY
    
    R. Perfetti e P. Merkel, "Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function", EUR J ENDOC, 143(6), 2000, pp. 717-725
33. Flint, A; Raben, A; Rehfeld, JF; Holst, JJ; Astrup, A
    The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
    INTERNATIONAL JOURNAL OF OBESITY
    
    A. Flint et al., "The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans", INT J OBES, 24(3), 2000, pp. 288-298
34. O'Harte, FPM; Mooney, MH; Lawlor, A; Flatt, PR
    N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    
    F.P.M. O'Harte et al., "N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo", BBA-GEN SUB, 1474(1), 2000, pp. 13-22
35. Katschinski, M
    Nutritional implications of cephalic phase gastrointestinal responses
    APPETITE
    
    M. Katschinski, "Nutritional implications of cephalic phase gastrointestinal responses", APPETITE, 34(2), 2000, pp. 189-196
36. Ebinger, M; Jehle, DR; Fussgaenger, RD; Fehmann, HC; Jehle, PM
    Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    M. Ebinger et al., "Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes", AM J P-ENDO, 279(1), 2000, pp. E88-E94
37. Vilsboll, T; Toft-Nielsen, MB; Krarup, T; Madsbad, S; Dinesen, B; Holst, JJ
    Evaluation of beta-cell secretory capacity using glucagon-like peptide 1
    DIABETES CARE
    
    T. Vilsboll et al., "Evaluation of beta-cell secretory capacity using glucagon-like peptide 1", DIABET CARE, 23(6), 2000, pp. 807-812
38. Hoentjen, F; Hopman, WPM; Maas, MIM; Jansen, JBMJ
    Role of circulating peptide YY in the inhibition of gastric acid secretionby dietary fat in humans
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
    
    F. Hoentjen et al., "Role of circulating peptide YY in the inhibition of gastric acid secretionby dietary fat in humans", SC J GASTR, 35(2), 2000, pp. 166-171
39. de Fonseca, FR; Navarro, M; Alvarez, E; Roncero, I; Chowen, JA; Maestre, O; Gomez, R; Munoz, RM; Eng, J; Blazquez, E
    Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    F.R. de Fonseca et al., "Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats", METABOLISM, 49(6), 2000, pp. 709-717
40. Yip, RGC; Wolfe, MM
    GIP biology and fat metabolism
    LIFE SCIENCES
    
    R.G.C. Yip e M.M. Wolfe, "GIP biology and fat metabolism", LIFE SCI, 66(2), 2000, pp. 91-103
41. Knudsen, LB; Nielsen, PF; Huusfeldt, PO; Johansen, NL; Madsen, K; Pedersen, FZ; Thogersen, H; Wilken, M; Agerso, H
    Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
    JOURNAL OF MEDICINAL CHEMISTRY
    
    L.B. Knudsen et al., "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", J MED CHEM, 43(9), 2000, pp. 1664-1669
42. O'Harte, FPM; Mooney, MH; Kelly, CMN; Flatt, PR
    Improved glycaemic control in obese diabetic ob/ob mice using N-terminallymodified gastric inhibitory polypeptide
    JOURNAL OF ENDOCRINOLOGY
    
    F.P.M. O'Harte et al., "Improved glycaemic control in obese diabetic ob/ob mice using N-terminallymodified gastric inhibitory polypeptide", J ENDOCR, 165(3), 2000, pp. 639-648
43. Siegel, EG; Seidenstucker, A; Gallwitz, B; Schmitz, F; Reinecke-Luthge, A; Kloppel, G; Folsch, UR; Schmidt, WE
    Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1
    JOURNAL OF ENDOCRINOLOGY
    
    E.G. Siegel et al., "Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1", J ENDOCR, 164(1), 2000, pp. 13-19
44. Lugari, R; Dell'Anna, C; Ugolotti, D; Dei Cas, A; Barilli, AL; Zandomeneghi, R; Marani, B; Lotti, M; Orlandini, A; Gnudi, A
    Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes
    HORMONE AND METABOLIC RESEARCH
    
    R. Lugari et al., "Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes", HORMONE MET, 32(10), 2000, pp. 424-428
45. Moro, F; Levenez, F; Nemoz-Gaillard, E; Pellissier, S; Plaisancie, P; Cuber, JC
    Release of guanylin immunoreactivity from the isolated vascularly perfusedrat colon
    ENDOCRINOLOGY
    
    F. Moro et al., "Release of guanylin immunoreactivity from the isolated vascularly perfusedrat colon", ENDOCRINOL, 141(7), 2000, pp. 2594-2599
46. Fritsche, A; Stefan, N; Hardt, E; Haring, H; Stumvoll, M
    Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion
    DIABETOLOGIA
    
    A. Fritsche et al., "Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion", DIABETOLOG, 43(7), 2000, pp. 852-858
47. Scrocchi, LA; Hill, ME; Saleh, J; Perkins, B; Drucker, DJ
    Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action
    DIABETES
    
    L.A. Scrocchi et al., "Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action", DIABETES, 49(9), 2000, pp. 1552-1560
48. Mojsov, S
    Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish
    AMERICAN ZOOLOGIST
    
    S. Mojsov, "Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish", AM ZOOLOG, 40(2), 2000, pp. 246-258
49. Brynes, AE; Edwards, CM; Jadhav, A; Ghatei, MA; Bloom, SR; Frost, GS
    Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes
    AMERICAN JOURNAL OF CLINICAL NUTRITION
    
    A.E. Brynes et al., "Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes", AM J CLIN N, 72(5), 2000, pp. 1111-1118
50. Jackson, KG; Zampelas, A; Knapper, JME; Roche, HM; Gibney, MJ; Kafatos, A; Gould, BJ; Wright, JW; Williams, CM
    Differences in glucose-dependent insulinotrophic polypeptide hormone and hepatic lipase in subjects of southern and northern Europe: implications forpostprandial lipemia
    AMERICAN JOURNAL OF CLINICAL NUTRITION
    
    K.G. Jackson et al., "Differences in glucose-dependent insulinotrophic polypeptide hormone and hepatic lipase in subjects of southern and northern Europe: implications forpostprandial lipemia", AM J CLIN N, 71(1), 2000, pp. 13-20
51. Caro, J; Wishner, KL
    Research advances in the treatment of type 2 diabetes mellitus
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    
    J. Caro e K.L. Wishner, "Research advances in the treatment of type 2 diabetes mellitus", INT J CL PR, 1999, pp. 23-33
52. Holst, JJ
    Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential
    TRENDS IN ENDOCRINOLOGY AND METABOLISM
    
    J.J. Holst, "Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential", TRENDS ENDO, 10(6), 1999, pp. 229-235
53. Hassan, M; Eskilsson, A; Nilsson, C; Jonsson, C; Jacobsson, H; Refai, E; Larsson, S; Efendic, S
    In vivo dynamic distribution of I-131-glucagon-like peptide-1 (7-36) amidein the rat studied by gamma camera
    NUCLEAR MEDICINE AND BIOLOGY
    
    M. Hassan et al., "In vivo dynamic distribution of I-131-glucagon-like peptide-1 (7-36) amidein the rat studied by gamma camera", NUCL MED BI, 26(4), 1999, pp. 413-420
54. Holst, JJ
    Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential
    CURRENT MEDICINAL CHEMISTRY
    
    J.J. Holst, "Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential", CURR MED CH, 6(11), 1999, pp. 1005-1017
55. Ahren, B; Pacini, G
    Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    B. Ahren e G. Pacini, "Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice", AM J P-ENDO, 277(6), 1999, pp. E996-E1004
56. Barragan, JM; Eng, J; Rodriguez, R; Blazquez, E
    Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    
    J.M. Barragan et al., "Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats", AM J P-ENDO, 277(5), 1999, pp. E784-E791
57. Siegel, EG; Gallwitz, B; Scharf, G; Mentlein, R; Morys-Wortmann, C; Folsch, UR; Schrezenmeir, J; Drescher, K; Schmidt, WE
    Biological activity of GLP-1-analogues with N-terminal modifications
    REGULATORY PEPTIDES
    
    E.G. Siegel et al., "Biological activity of GLP-1-analogues with N-terminal modifications", REGUL PEPT, 79(2-3), 1999, pp. 93-102
58. Toft-Nielsen, MB; Madsbad, S; Holst, JJ
    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
    DIABETES CARE
    
    M.B. Toft-Nielsen et al., "Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients", DIABET CARE, 22(7), 1999, pp. 1137-1143
59. Anini, Y; Fu-Cheng, XM; Cuber, JC; Kervran, A; Chariot, J; Roze, C
    Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
    
    Y. Anini et al., "Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat", PFLUG ARCH, 438(3), 1999, pp. 299-306
60. Meurer, JA; Colca, JR; Burton, PS; Elhammer, AP
    Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39)
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    J.A. Meurer et al., "Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39)", METABOLISM, 48(6), 1999, pp. 716-724
61. Burcelin, R; Dolci, W; Thorens, B
    Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    R. Burcelin et al., "Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1", METABOLISM, 48(2), 1999, pp. 252-258
62. Freyse, EJ; Knospe, S; Becher, T; El Hag, O; Goke, B; Fischer, U
    Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic
    METABOLISM-CLINICAL AND EXPERIMENTAL
    
    E.J. Freyse et al., "Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic", METABOLISM, 48(1), 1999, pp. 134-137
63. Deacon, CF; Holst, JJ; Carr, RD
    Glucagon-like peptide-1: A basis for new approaches to the management of diabetes
    DRUGS OF TODAY
    
    C.F. Deacon et al., "Glucagon-like peptide-1: A basis for new approaches to the management of diabetes", DRUGS TODAY, 35(3), 1999, pp. 159-170
64. Claustre, J; Brechet, S; Plaisancie, P; Chayvialle, JA; Cuber, JC
    Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation
    JOURNAL OF ENDOCRINOLOGY
    
    J. Claustre et al., "Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation", J ENDOCR, 162(2), 1999, pp. 271-278
65. Holz, GG; Leech, CA; Heller, RS; Castonguay, M; Habener, JF
    cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells - A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    G.G. Holz et al., "cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells - A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)", J BIOL CHEM, 274(20), 1999, pp. 14147-14156
66. Gutzwiller, JP; Goke, B; Drewe, J; Hildebrand, P; Ketterer, S; Handschin, D; Winterhalder, R; Conen, D; Beglinger, C
    Glucagon-like peptide-1: a potent regulator of food intake in humans
    GUT
    
    J.P. Gutzwiller et al., "Glucagon-like peptide-1: a potent regulator of food intake in humans", GUT, 44(1), 1999, pp. 81-86
67. Meeran, K; O'Shea, D; Edwards, CMB; Turton, MD; Heath, MM; Gunn, I; Abusnana, S; Rossi, M; Small, CJ; Goldstone, AP; Taylor, GM; Sunter, D; Steere, J; Choi, SJ; Ghatei, MA; Bloom, SR
    Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat
    ENDOCRINOLOGY
    
    K. Meeran et al., "Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat", ENDOCRINOL, 140(1), 1999, pp. 244-250
68. Nauck, MA
    Is glucagon-like peptide 1 an incretin hormone?
    DIABETOLOGIA
    
    M.A. Nauck, "Is glucagon-like peptide 1 an incretin hormone?", DIABETOLOG, 42(3), 1999, pp. 373-379
69. Sandhu, H; Wiesenthal, SR; MacDonald, PE; McCall, RH; Tchipashvili, V; Rashid, S; Satkunarajah, M; Irwin, DM; Shi, ZQ; Brubaker, PL; Wheeler, MB; Vranic, M; Efendic, S; Giacca, A
    Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs
    DIABETES
    
    H. Sandhu et al., "Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs", DIABETES, 48(5), 1999, pp. 1045-1053
70. O'Harte, FPM; Mooney, MH; Flatt, PR
    NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity
    DIABETES
    
    F.P.M. O'Harte et al., "NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity", DIABETES, 48(4), 1999, pp. 758-765
71. Long, SJ; Sutton, JA; Amaee, WB; Giouvanoudi, A; Spyrou, NM; Rogers, PJ; Morgan, LV
    No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man
    BRITISH JOURNAL OF NUTRITION
    
    S.J. Long et al., "No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man", BR J NUTR, 81(4), 1999, pp. 273-279
72. Hiroyoshi, M; Tateishi, K; Yasunami, Y; Maeshiro, K; Ono, J; Matsuoka, Y; Ikeda, S
    Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes
    AMERICAN JOURNAL OF GASTROENTEROLOGY
    
    M. Hiroyoshi et al., "Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes", AM J GASTRO, 94(4), 1999, pp. 976-981
73. ROSSELIN G; LECLERCQMEYER V; BOISSART C; PESSAH M; MALAISSE WJ
    GLP-1 RECEPTORS IN GOLDEN SYRIAN-HAMSTER ISLETS - IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION
    ENDOCRINE
    
    G. Rosselin et al., "GLP-1 RECEPTORS IN GOLDEN SYRIAN-HAMSTER ISLETS - IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION", ENDOCRINE, 8(3), 1998, pp. 323-330
74. WILLMS B; IDOWU K; HOLST JJ; CREUTZFELDT W; NAUCK MA
    OVERNIGHT GLP-1 NORMALIZES FASTING BUT NOT DAYTIME PLASMA-GLUCOSE LEVELS IN NIDDM PATIENTS
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    B. Willms et al., "OVERNIGHT GLP-1 NORMALIZES FASTING BUT NOT DAYTIME PLASMA-GLUCOSE LEVELS IN NIDDM PATIENTS", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 106(2), 1998, pp. 103-107
75. NAUCK MA
    GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) - A POTENT GUT HORMONE WITH A POSSIBLE THERAPEUTIC PERSPECTIVE
    Acta diabetologica
    
    M.A. Nauck, "GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) - A POTENT GUT HORMONE WITH A POSSIBLE THERAPEUTIC PERSPECTIVE", Acta diabetologica, 35(3), 1998, pp. 117-129
76. HANSEN BF; JENSEN P; NEPPERCHRISTENSEN E; SKJOLSTRUP B
    EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON INSULIN-STIMULATED RAT SKELETAL-MUSCLE GLUCOSE-TRANSPORT
    Acta diabetologica
    
    B.F. Hansen et al., "EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON INSULIN-STIMULATED RAT SKELETAL-MUSCLE GLUCOSE-TRANSPORT", Acta diabetologica, 35(2), 1998, pp. 101-103
77. BRYNES AE; FROST GS; EDWARDS MB; GHATEL MA; BLOOM SR
    PLASMA GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) RESPONSE TO LIQUID-PHASE, SOLID-PHASE, AND MEALS OF DIFFERING LIPID-COMPOSITION
    Nutrition
    
    A.E. Brynes et al., "PLASMA GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) RESPONSE TO LIQUID-PHASE, SOLID-PHASE, AND MEALS OF DIFFERING LIPID-COMPOSITION", Nutrition, 14(5), 1998, pp. 433-436
78. Blazquez, E; Alvarez, E; Roncero, I; Rodriguez-Fonseca, F; Chowen, JA; Zueco, JA
    Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide
    MOLECULAR NEUROBIOLOGY
    
    E. Blazquez et al., "Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide", MOL NEUROB, 18(2), 1998, pp. 157-173
79. FEHMANN HC; PRACHT A; GOKE B
    HIGH-LEVEL EXPRESSION OF THE GLP-I RECEPTOR RESULTS IN RECEPTOR DESENSITIZATION
    Pancreas
    
    H.C. Fehmann et al., "HIGH-LEVEL EXPRESSION OF THE GLP-I RECEPTOR RESULTS IN RECEPTOR DESENSITIZATION", Pancreas, 17(3), 1998, pp. 309-314
80. NAITO H; SASAKI I; MATSUNO S
    SURGICAL ASPECT OF ENTEROINSULAR AXIS AFTER GASTROINTESTINAL SURGERY WITH REFERENCE TO INCRETIN SECRETION
    Pancreas
    
    H. Naito et al., "SURGICAL ASPECT OF ENTEROINSULAR AXIS AFTER GASTROINTESTINAL SURGERY WITH REFERENCE TO INCRETIN SECRETION", Pancreas, 16(3), 1998, pp. 370-378
81. PERFETTI R; BARNETT PS; MATHUR R; EGAN JM
    NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE-2 DIABETES
    Diabetes/metabolism reviews
    
    R. Perfetti et al., "NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE-2 DIABETES", Diabetes/metabolism reviews, 14(3), 1998, pp. 207-225
82. SEIFARTH C; BERGMANN J; HOLST JJ; RITZEL R; SCHMIEGEL W; NAUCK MA
    PROLONGED AND ENHANCED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) AFTER ORAL SUCROSE DUE TO ALPHA-GLUCOSIDASE INHIBITION (ACARBOSE) IN TYPE-2 DIABETIC-PATIENTS
    Diabetic medicine
    
    C. Seifarth et al., "PROLONGED AND ENHANCED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) AFTER ORAL SUCROSE DUE TO ALPHA-GLUCOSIDASE INHIBITION (ACARBOSE) IN TYPE-2 DIABETIC-PATIENTS", Diabetic medicine, 15(6), 1998, pp. 485-491
83. YANG H; EGAN JM; WANG Y; MOYES CD; ROTH J; MONTROSE MH; MONTROSERAFIZADEH C
    GLP-1 ACTION IN L6 MYOTUBES IS VIA A RECEPTOR DIFFERENT FROM THE PANCREATIC GLP-1 RECEPTOR
    American journal of physiology. Cell physiology
    
    H. Yang et al., "GLP-1 ACTION IN L6 MYOTUBES IS VIA A RECEPTOR DIFFERENT FROM THE PANCREATIC GLP-1 RECEPTOR", American journal of physiology. Cell physiology, 44(3), 1998, pp. 675-683
84. OHARTE FPM; ABDELWAHAB YHA; CONLON JM; FLATT PR
    AMINO-TERMINAL GLYCATION OF GASTRIC-INHIBITORY POLYPEPTIDE ENHANCES ITS INSULINOTROPIC ACTION ON CLONAL PANCREATIC B-CELLS
    Biochimica et biophysica acta (G). General subjects
    
    F.P.M. Oharte et al., "AMINO-TERMINAL GLYCATION OF GASTRIC-INHIBITORY POLYPEPTIDE ENHANCES ITS INSULINOTROPIC ACTION ON CLONAL PANCREATIC B-CELLS", Biochimica et biophysica acta (G). General subjects, 1425(2), 1998, pp. 319-327
85. WETTERGREN A; WOJDEMANN M; HOLST JJ
    THE INHIBITORY EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON ANTRAL MOTILITY IS ANTAGONIZED BY ITS N-TERMINALLY TRUNCATED PRIMARY METABOLITE GLP-1 (9-36)AMIDE
    Peptides (New York, N.Y. 1980)
    
    A. Wettergren et al., "THE INHIBITORY EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON ANTRAL MOTILITY IS ANTAGONIZED BY ITS N-TERMINALLY TRUNCATED PRIMARY METABOLITE GLP-1 (9-36)AMIDE", Peptides (New York, N.Y. 1980), 19(5), 1998, pp. 877-882
86. WETTERGREN A; PRIDAL L; WOJDEMANN M; HOLST JJ
    AMIDATED AND NON-AMIDATED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - NONPANCREATIC EFFECTS (CEPHALIC PHASE ACID-SECRETION) AND STABILITY IN PLASMA IN HUMANS
    Regulatory peptides
    
    A. Wettergren et al., "AMIDATED AND NON-AMIDATED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - NONPANCREATIC EFFECTS (CEPHALIC PHASE ACID-SECRETION) AND STABILITY IN PLASMA IN HUMANS", Regulatory peptides, 77(1-3), 1998, pp. 83-87
87. GIRALT M; VERGARA P
    SYMPATHETIC PATHWAYS MEDIATE GLP-1 ACTIONS IN THE GASTROINTESTINAL-TRACT OF THE RAT
    Regulatory peptides
    
    M. Giralt e P. Vergara, "SYMPATHETIC PATHWAYS MEDIATE GLP-1 ACTIONS IN THE GASTROINTESTINAL-TRACT OF THE RAT", Regulatory peptides, 74(1), 1998, pp. 19-25
88. NAUCK MA; SAUERWALD A; RITZEL R; HOLST JJ; SCHMIEGEL W
    INFLUENCE OF GLUCAGON-LIKE PEPTIDE 1 ON FASTING GLYCEMIA IN TYPE-2 DIABETIC-PATIENTS TREATED WITH INSULIN AFTER SULFONYLUREA SECONDARY FAILURE
    Diabetes care
    
    M.A. Nauck et al., "INFLUENCE OF GLUCAGON-LIKE PEPTIDE 1 ON FASTING GLYCEMIA IN TYPE-2 DIABETIC-PATIENTS TREATED WITH INSULIN AFTER SULFONYLUREA SECONDARY FAILURE", Diabetes care, 21(11), 1998, pp. 1925-1931
89. TODD JF; EDWARDS CMB; GHATEI MA; MATHER HM; BLOOM SR
    SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-I IMPROVES POSTPRANDIAL GLYCEMIC CONTROL OVER A 3-WEEK PERIOD IN PATIENTS WITH EARLY-TYPE-2 DIABETES
    Clinical science
    
    J.F. Todd et al., "SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-I IMPROVES POSTPRANDIAL GLYCEMIC CONTROL OVER A 3-WEEK PERIOD IN PATIENTS WITH EARLY-TYPE-2 DIABETES", Clinical science, 95(3), 1998, pp. 325-329
90. Edwards, CMB; Todd, JF; Ghatei, MA; Bloom, SR
    Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects
    CLINICAL SCIENCE
    
    C.M.B. Edwards et al., "Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects", CLIN SCI, 95(6), 1998, pp. 719-724
91. OHARTE FPM; GRAY AM; FLATT PR
    GASTRIC-INHIBITORY POLYPEPTIDE AND EFFECTS OF GLYCATION ON GLUCOSE-TRANSPORT AND METABOLISM IN ISOLATED MOUSE ABDOMINAL MUSCLE
    Journal of Endocrinology
    
    F.P.M. Oharte et al., "GASTRIC-INHIBITORY POLYPEPTIDE AND EFFECTS OF GLYCATION ON GLUCOSE-TRANSPORT AND METABOLISM IN ISOLATED MOUSE ABDOMINAL MUSCLE", Journal of Endocrinology, 156(2), 1998, pp. 237-243
92. SCHIRRA J; LEICHT P; HILDEBRAND P; BEGLINGER C; ARNOLD R; GOKE B; KATSCHINSKI M
    MECHANISMS OF THE ANTIDIABETIC ACTION OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    Journal of Endocrinology
    
    J. Schirra et al., "MECHANISMS OF THE ANTIDIABETIC ACTION OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS", Journal of Endocrinology, 156(1), 1998, pp. 177-186
93. SCHIRRA J; STURM K; LEICHT P; ARNOLD R; GOKE B; KATSCHINSKI M
    EXENDIN(9-39)AMIDE IS AN ANTAGONIST OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN HUMANS
    The Journal of clinical investigation
    
    J. Schirra et al., "EXENDIN(9-39)AMIDE IS AN ANTAGONIST OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN HUMANS", The Journal of clinical investigation, 101(7), 1998, pp. 1421-1430
94. BEAK SA; HEATH MM; SMALL CJ; MORGAN DGA; GHATEI MA; TAYLOR AD; BUCKINGHAM JC; BLOOM SR; SMITH DM
    GLUCAGON-LIKE PEPTIDE-1 STIMULATES LUTEINIZING-HORMONE-RELEASING HORMONE-SECRETION IN A RODENT HYPOTHALAMIC NEURONAL CELL-LINE
    The Journal of clinical investigation
    
    S.A. Beak et al., "GLUCAGON-LIKE PEPTIDE-1 STIMULATES LUTEINIZING-HORMONE-RELEASING HORMONE-SECRETION IN A RODENT HYPOTHALAMIC NEURONAL CELL-LINE", The Journal of clinical investigation, 101(6), 1998, pp. 1334-1341
95. RYAN AS; EGAN JM; HABENER JF; ELAHI D
    INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1-(7-37) APPEARS NOT TO AUGMENT INSULIN-MEDIATED GLUCOSE-UPTAKE IN YOUNG MEN DURING EUGLYCEMIA
    The Journal of clinical endocrinology and metabolism
    
    A.S. Ryan et al., "INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1-(7-37) APPEARS NOT TO AUGMENT INSULIN-MEDIATED GLUCOSE-UPTAKE IN YOUNG MEN DURING EUGLYCEMIA", The Journal of clinical endocrinology and metabolism, 83(7), 1998, pp. 2399-2404
96. DAMHOLT AB; BUCHAN AMJ; KOFOD H
    GLUCAGON-LIKE-PEPTIDE-1 SECRETION FROM CANINE L-CELLS IS INCREASED BYGLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE BUT UNAFFECTED BY GLUCOSE
    Endocrinology
    
    A.B. Damholt et al., "GLUCAGON-LIKE-PEPTIDE-1 SECRETION FROM CANINE L-CELLS IS INCREASED BYGLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE BUT UNAFFECTED BY GLUCOSE", Endocrinology, 139(4), 1998, pp. 2085-2091
97. BRUBAKER PL; SCHLOOS J; DRUCKER DJ
    REGULATION OF GLUCAGON-LIKE PEPTIDE-1 SYNTHESIS AND SECRETION IN THE GLUTAG ENTEROENDOCRINE CELL-LINE
    Endocrinology
    
    P.L. Brubaker et al., "REGULATION OF GLUCAGON-LIKE PEPTIDE-1 SYNTHESIS AND SECRETION IN THE GLUTAG ENTEROENDOCRINE CELL-LINE", Endocrinology, 139(10), 1998, pp. 4108-4114
98. PRINTZ H; REITER S; SAMADI N; EBRAHIMSADE S; KIRCHNER R; ARNOLD R; GOKE B
    GLP-1 RELEASE IN MAN AFTER LOWER LARGE-BOWEL RESECTION OR INTRARECTALGLUCOSE-ADMINISTRATION
    Digestion
    
    H. Printz et al., "GLP-1 RELEASE IN MAN AFTER LOWER LARGE-BOWEL RESECTION OR INTRARECTALGLUCOSE-ADMINISTRATION", Digestion, 59(6), 1998, pp. 689-695
99. TOFTNIELSEN M; MADSBAD S; HOLST JJ
    EXAGGERATED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) COULD CAUSE REACTIVE HYPOGLYCEMIA
    Diabetologia
    
    M. Toftnielsen et al., "EXAGGERATED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) COULD CAUSE REACTIVE HYPOGLYCEMIA", Diabetologia, 41(10), 1998, pp. 1180-1186
100. OHARTE FPM; ABDELWAHAB YHA; CONLON JM; FLATT PR
     GLYCATION OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE - CHARACTERIZATION AND IMPAIRED ACTION ON RAT INSULIN-SECRETING CELLS
     Diabetologia
     
     F.P.M. Oharte et al., "GLYCATION OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE - CHARACTERIZATION AND IMPAIRED ACTION ON RAT INSULIN-SECRETING CELLS", Diabetologia, 41(10), 1998, pp. 1187-1193